lucky number
Leiria focuses on emergency social housingMaverick McNealy birdies the last hole at Sea Island to finally become PGA Tour winner
Axarquía against gender violence for International day
Social Don't miss out on the headlines from Social. Followed categories will be added to My News. Coalition senator Matt Canavan says he is still unsure if he will support the Albanese government’s social media ban for kids under 16. The world-leading policy has received broad support in principle, but parliamentarians have had little time to scrutinise the legislation and privacy has emerged as a key concern for the opposition. Senator Canavan said on Tuesday he understood the need for the ban but did not think there was a need “to rush it”. Coalition senator Matt Canavan says he is still unsure if he will support the government’s social media ban. Picture: NewsWire / Gary Ramage “I certainly think the Bill needs major changes, and regardless of the changes, I remain unimpressed with this condensed timeframe to analyse the Bill,” Senator Canavan told the ABC. “There is widespread support across the parliament for something like this. “And given that, there’s just no real need, I think, to rush it. “I don’t think that support is going to somehow disappear over the summer break. “We can, I think, just pause here, come back and do this.” Senator Canavan also said the ban would affect social media users of all ages “because once you have to try and verify someone’s age under 16, you’re going to have to verify everyone’s age to check their age”. The Greens have also taken issue with the lack of scrutiny over the ban, with MP Max Chandler Mather saying there were “a lot of unresolved questions”. Meanwhile, independent MP Zoe Daniel said the legislation let social media platforms “off the hook”. Independent MP Zoe Daniel says the social media ban would let platforms ‘off the hook’. Picture: NewsWire / Martin Ollman She introduced her alternative proposal in a private member’s Bill on Monday. “We need to get the platforms to take responsibility for what is in their environment, and actually, it would make an age ban redundant if we were to put in this kind of safety by design and a duty of care and hold the platforms accountable for what’s happening in their spaces,” she told the ABC. “You wouldn’t actually need an age ban.” Originally published as Hesitancy over federal government’s social media ban Join the conversation Add your comment to this story To join the conversation, please log in. Don't have an account? Register Join the conversation, you are commenting as Logout More related stories Social Star confronts fans after ‘monkey’ slur A social media star with 33 million followers has called out a group of young fans after a disturbing incident follwing his Aussie tour. Read more National ‘Blood on our hands’: Aussie parents’ plea on social media ban Mums and dads around Australia are calling on MPs to have the courage to vote for world-leading legislation. They fear if it does not pass, more children’s lives will be lost. Read more
Janux Therapeutics, Inc. ( NASDAQ:JANX – Get Free Report ) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at $12,196,264.26. This represents a 10.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link . David Alan Campbell also recently made the following trade(s): Janux Therapeutics Stock Down 1.9 % JANX stock opened at $54.10 on Friday. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71. The firm’s 50-day moving average is $54.43 and its 200 day moving average is $47.43. Institutional Investors Weigh In On Janux Therapeutics Several hedge funds have recently made changes to their positions in JANX. Charles Schwab Investment Management Inc. increased its stake in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after buying an additional 156,675 shares during the period. Ally Bridge Group NY LLC purchased a new position in Janux Therapeutics during the 3rd quarter valued at about $4,943,000. Algert Global LLC bought a new stake in shares of Janux Therapeutics in the 3rd quarter valued at about $1,112,000. FMR LLC raised its holdings in shares of Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after purchasing an additional 47,075 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics in the 3rd quarter worth approximately $940,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analyst Weigh In Several equities analysts have recently commented on the stock. Scotiabank boosted their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. Stifel Nicolaus raised their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. BTIG Research boosted their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Finally, Leerink Partners lifted their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Buy” and an average target price of $89.90. Get Our Latest Stock Report on Janux Therapeutics Janux Therapeutics Company Profile ( Get Free Report ) Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Further Reading Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .